LONDON — When Europe’s largest cardiology convention opened right here this previous Friday, one of many first classes centered completely on a single drug.
It lower the danger of issues from a standard type of coronary heart failure, researchers reported. It helped enhance the construction of the center in addition to its operate. It even saved the lives of individuals with Covid-19 — a respiratory an infection of all issues.
“Now on to one thing completely totally different,” Richard Pratley, a diabetes specialist at AdventHealth in Orlando, advised the standing-room-only crowd as he launched a trial of the drug in kidney illness.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the pharma trade — by subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
View All Plans
